The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
US genetic medicines developer GenEdit today revealed a multiyear collaboration and license agreement with Genentech as well as a $24 million Series A1 financing round. 23 January 2024
Small biotechs continue to show more interest in a public listing in 2024, with ArriVent Biopharma the latest to opt for an initial public offering (IPO) in the USA. 23 January 2024
Positive results in a Phase IIb trial could point the way to a breakthrough in non-alcoholic steatohepatitis (NASH) for West Coast-based biotech Sagimet Biosciences. 23 January 2024
French pharma major Sanofi has entered into a definitive agreement to acquire US biotech Inhibrx following the spin-off of non-INBRX-101 assets into ‘New Inhibrx’. 23 January 2024
Privately-held Danish dermatology specialist LEO Pharma says it has finalized the acquisition of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals following the US firm’s Chapter 11 bankruptcy filing. 23 January 2024
Ionis Pharmaceuticals yesterday announced positive top-line results for the Phase III OASIS-HAE study of donidalorsen in people with hereditary angioedema (HAE), with the news sending the US RNA-targeted drug developer’s shares up more than 5% to $53.58. 23 January 2024
US biotech major Gilead Sciences is staring down the barrel of a 10% decline in its market value on Monday due to a setback with a key oncology asset. 22 January 2024
Oxford Nanopore Technologies, a UK company delivering nanopore-based molecular sensing technology, has announced the expansion of its leadership team. 22 January 2024
Despite an initial 3.4% dip, shares of Swiss clinical-stage biotech AC Immune were unchanged by early afternoon, despite announcing that a major licensing partner has pulled out of their deal. 22 January 2024
French clinical-stage biotech Abivax , which recently completed an around $236 million financing, saw its shares edge up 2.2% to 10.48 euros today, after the company provided an outlook on its 2024 strategic priorities and milestones. 22 January 2024
Bristol Myers Squibb has announced impressive results from the Phase III CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab). 22 January 2024
German pharma major Bayer today revealed that it has received authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Eylea (aflibercept) 8mg in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), and visual impairment due to diabetic macular oedema (DMO). 22 January 2024